FDA probes long-acting Zyprexa safety after 2 patients die

Tracy Staton Two patients have died unexpectedly after their Zyprexa Relprevv injections, and the FDA is now investigating. The agency says the patients died three to four days after ...

Medivir recruits a new head of Commercial Operations

barbara.lempert Stockholm — Medivir AB (OMX: MVIR) strengthens the executive management team by recruiting Henrik Krook as Executive VP Commercial. Henrik will be operationally and ...

Teva Pharma breaks M&A silence with bite-sized MicroDose buyout

Ryan McBride Known previously for rapid growth via acquisitions, Teva Pharmaceutical had recently been quiet on the buyout front–until Monday. The Israel-based pharma company ...

Newly minted Sanofi diabetes med fails to impress German pricing regulators

Tracy Staton Sanofi's new diabetes drug hit a setback in Germany. The country's increasingly strict pricing regulators say Lyxumia delivers "no additional benefit" ...

Repros Therapeutics Inc. Announces Proposed Public Offering of Common Stock

barbara.lempert THE WOODLANDS, Texas, June 17, 2013 (GLOBE NEWSWIRE) — Repros Therapeutics Inc. (Nasdaq:RPRX) today announced that it has commenced an underwritten public offering ...

Adamas claims success with new and improved Parkinson’s drug

John Carroll Investigators say that the lead drug–ADS-5102, reformulated in a way designed to reduce the severity of side effects that plague patients–demonstrated a statistically ...

AstraZeneca homes in on new HQ and research site in Cambridge

Tracy Staton Over the next three years the pharma company plans to build a $ 500 million complex on an 11-acre site at the Cambridge BioMedical Campus. FiercePharma News

Allergan Survey: 1 in 5 Women Embarrassed to Talk About OAB

barbara.lempert New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors Even When Medicines Have Already Been Tried, Candid Conversations ...

Booming Alexion breaks ground on $140M global HQ

John Carroll Now that Alexion has established its reputation for marketing new drugs for ultra-rare diseases with the success of Soliris, the most expensive drug on the planet, the ...

Who wins after SCOTUS pay-for-delay decision? Lawyers

Tracy Staton The pay-for-delay ruling is in. That means legal experts and industry analysts are poring over the decision, trying to assess its consequences. Any consensus? By eschewing ...

Is It Time To Overhaul The FDA? A Panel With Pharmalot

esilverman Is the FDA doing the right job? Some critics argue the agency fails to move fast enough to approve new drugs and still others maintain some decisions may be compromised ...

R&D cutbacks loom at Millennium’s Cambridge ops

John Carroll The new president at Millennium Pharmaceuticals has been trying to maintain a careful balancing act in recent weeks, trying to reassure staffers about Takeda's commitment ...
© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS